Live Procurement Signals Bloomberg-Inspired UI U.S. Tariff Intelligence

Initializing official-source tariff headline feed Loading CBP CSMS operational updates Loading Federal Register trade notices Initializing official-source tariff headline feed Loading CBP CSMS operational updates Loading Federal Register trade notices

Global Tariff Command Center

US Tariff Intelligence Desk

Last updated: 2026-03-30 Audience: Siemens Healthineers Procurement Coverage: U.S. tariffs + countermeasures BREAKINGSection 122: 10% global tariff effective Feb 24, 2026

Section 122 expiry countdown (150 days from Feb 24) Calculating... — Congressional approval needed to extend beyond Jul 24, 2026

⚡ BREAKING / Updated Mar 30, 2026 — Section 122 temporary import duty remains operative at 10%:

After the U.S. Supreme Court struck down IEEPA tariffs on Feb 20, 2026 (24-1287, 6-3 ruling), the White House invoked Section 122 to impose a temporary global import surcharge.
The operative surcharge is 10% effective Feb 24, 2026 at 00:01 ET for up to 150 days (expires around Jul 24, 2026 unless Congress approves extension). Exemptions include pharmaceuticals/pharma ingredients, certain agriculture, critical minerals/metals, some electronics, USMCA-qualifying goods, and Section 232-covered goods (no stacking).
New USTR Section 301 investigations (initiated Mar 12; published Mar 17) remain in process, with comments due Apr 15 and hearings starting Apr 28.

Confirm operative tariff treatment and HTS applicability with customs counsel or your customs broker before shipment booking.

Sources: [White House proclamation] [White House fact sheet] [Federal Register (forced labor)] [Federal Register (structural excess capacity)] [SCOTUS opinion] [CNBC]

Last updated 2026-03-30

This reflects the last homepage content update, not the background live-feed refresh time.

Latest material change New Section 301 investigations

Homepage alert and timeline now include the Mar 12 USTR investigation tracks published in the Federal Register on Mar 17.

Why it can look the same Most daily runs are feed refreshes

The Live Feeds tab updates often, but the homepage only changes when a verified tariff-policy development is material enough to surface.

What The Latest Changes Mean For Siemens Healthineers As A Business

Tariff pressure remains a material earnings risk: Siemens Healthineers flagged around EUR 400M FY2026 tariff impact, indicating tariff costs remain financially meaningful even after the IEEPA ruling.
[Bloomberg]
The U.S. import-cost baseline is still elevated: Yale Budget Lab's published checkpoint after Section 122 shows a higher effective tariff environment than pre-2025 norms, which sustains margin and pricing pressure.
[Yale Budget Lab]
Policy risk remains open-ended: The two USTR Section 301 investigations can create additional duty exposure in strategic manufacturing and compliance-sensitive supply chains once the process concludes.
[Federal Register: forced labor track] [Federal Register: structural excess capacity track]

What The Latest Changes Mean For Siemens Healthineers Procurement

Treat 10% Section 122 as the default working layer for non-exempt imports until policy changes are formally published; keep landed-cost models on a 10% base-case and a post-July expiry decision branch.
[White House proclamation]
Prioritize exemption validation at SKU level: pharmaceuticals/pharma ingredients, some electronics, USMCA-qualifying goods, and Section 232-covered products have specific treatment; classification errors are now high-cost errors.
[White House fact sheet]
Use the Apr 15/Apr 28 Section 301 process window as an execution deadline: collect supplier data, forced-labor controls, and excess-capacity exposure now so category teams can react quickly if duties are proposed.
[Federal Register: comments/hearings calendar] [Federal Register: comments/hearings calendar]

Executive Snapshot

As of 2026-03-30. This view separates active trade measures from contested/conditional measures and highlights the highest procurement-impact categories for Siemens Healthineers global sourcing teams.

Active Tariff Regimes (Confirmed)

Section 232 Steel/Aluminum: 50% on all countries (UK 25%). Eff. Jun 4, 2025. [FR Proc. 10947]
Section 232 Autos & Parts: 25% on passenger vehicles. Eff. Apr 3, 2025. [FR Proc. 10908]
Section 232 Semiconductors: 25% on covered chips and SME. Eff. Jan 15, 2026. [FR Proc. 11002]
Section 232 Copper: 50% on semi-finished copper derivatives. Eff. Aug 1, 2025. [FR Proc. 10962]
Section 301 China Strategic: Elevated duties on EVs, batteries, solar, cranes, selected medical products. [USTR 2024]
Section 122 Global Surcharge: Operative 10% on covered non-exempt goods from Feb 24, 2026 under the White House proclamation. Statutory maximum is 15% for up to 150 days. [White House proclamation] [White House Fact Sheet]
Branded Pharma 100%: 100% tariff on branded/patented drugs (exemption for U.S. manufacturing investment). Eff. Oct 1, 2025. [AHA/White House]

Contested / Under Investigation

IEEPA tariffs invalidated: SCOTUS ruled IEEPA does not authorize broad tariff programs (Feb 20, 2026, 6-3). All IEEPA-derived rates struck down; awaiting CBP unwinding guidance. [SCOTUS] [SCOTUSblog analysis]
Medical Devices Section 232: BIS investigation opened Sep 24, 2025. Covers CT/MRI/X-ray, pacemakers, stents, ventilators, PPE. Report due May 30, 2026; President has 90 days to act. [Supply Chain Dive] [White & Case]
Pharma Section 232: Investigation ongoing (initiated Apr 1, 2025). Generic/branded APIs, finished drugs, biologics in scope. [EY Global]
Section 122 duration risk: Section 122 expires ~Jul 24, 2026. Congressional approval required to extend beyond 150 days. If not extended, tariff lapses — creating sourcing volatility. [Axios]
India interim deal: US-India Interim Agreement reducing IEEPA reciprocal rates to 18% on certain goods — IEEPA component now moot post-SCOTUS, but bilateral deal framework may survive. [Tax Foundation tracker]

Priority Actions for Procurement

Confirm current impact: Run all open POs through the Tariff Calculator with the Section 122 10% layer only for covered non-exempt commodities. [Use Tariff Calculator tab]
Pharma/API sourcing: Verify supplier country and product classification — UK has 0% pharma deal. Branded pharma 100% tariff already active. Generic APIs face Section 232 investigation risk. [UK deal FR]
Imaging supply chain: CT, MRI, X-ray components face Section 232 (steel 50% / semi 25%) plus any applicable Section 122 10% non-exempt layer, with potential Medical Devices Section 232 upside risk by mid-2026. [Bloomberg SHS impact]
Steel/copper contracts: Re-confirm force-majeure and price-escalation clauses — 50% steel/copper rates fully active since Jun/Aug 2025, not disputed by SCOTUS ruling. [CNBC — industries still facing higher rates]
China exposure: Section 301 strategic tariffs remain fully active and unaffected by SCOTUS ruling. Anti-circumvention enforcement (melt-and-pour, transshipment) actively enforced. [USTR Section 301]
Monitor GAPS tab: Retaliation schedules for India, Japan, EU, South Korea still incomplete. SHS category-level SKU mapping not built. Medical Devices S.232 report due May 30 — critical watch date. [Gaps tab]

Siemens Healthineers — Tariff Impact Intelligence

This view consolidates tariff exposure specific to Siemens Healthineers (SHS) product portfolio and procurement categories. Data sourced from SHS investor disclosures, Bloomberg, MedTech Dive, and regulatory filings. For internal procurement planning only.

Financial Impact Overview

FY2025 tariff hit: ~€200M actual impact on earnings.
Source: MedTech Dive, Nov 2025
FY2026 projected impact: €400M (~$460M) — double FY2025.
Source: Bloomberg, Nov 5 2025
Mitigation spend: €200–300M planned for production relocation and supplier diversification.
Source: Radiology Business, 2025
Impact split: Imaging and Advanced Therapies segments most exposed; Varian and Diagnostics comparatively lower impact.

Product Categories at Risk

Computed Tomography (CT): Steel/aluminum chassis components (Section 232 50%); semiconductor detector arrays (Section 232 25%); copper wiring harnesses (Section 232 50%). Additionally under Medical Devices Section 232 investigation.
Source: Supply Chain Dive
MRI Systems: Superconducting magnets (copper, specialized alloys 50%); electronics (semis 25%); cryogenic components. Same Section 232 medical device probe covers MRI.
Source: White & Case
X-Ray / Angio / PET: Detector panels, X-ray tubes contain steel frames and semiconductor components. Section 301 (China) applies to sourced electrical components.
Diagnostics / Lab: Less affected by current Section 232 programs. However, reagent/API supply chains may hit pharma tariff if derived products are reclassified.
Varian (Radiation Oncology): Lower direct tariff exposure per SHS guidance; U.S. manufacturing provides domestic buffer.

Strategic Procurement Signals

No price increases yet: As of mid-2025 SHS had not raised prices, absorbing tariffs in margins — but flagged potential future pass-through.
Source: Radiology Business
Production relocation: SHS is actively evaluating moving production hubs to mitigate tariff exposure, though no confirmed moves as of Feb 2026.
Supplier diversification: Actively building second-source supply chains away from China for electronics, metals, and components.
UK pharma deal advantage: SHS diagnostics reagents/kits sourced from UK may benefit from 0% pharma tariff under US-UK deal. Confirm HTS classification.
Source: Baker Donelson
Medical device exemption watch: Section 232 medical device investigation (report due May 2026) could impose additional tariffs or — if exclusions are granted — provide relief. File comment letters with BIS before public comment deadline.

SHS Procurement Category Tariff Exposure Matrix

Mapping of SHS product/spend categories to applicable tariff regimes. Rates shown are additive where non-stacking rules do not apply.

SHS Category	Key Inputs	Primary Tariff Regime	Rate Range	Status	Notes
CT Systems	Steel housings, Al gantry, Cu wiring, detector chips	Section 232 (metal + semi) + Section 122	25–65%	HIGH RISK	Medical device S.232 probe adds further upside risk by mid-2026
MRI Systems	Superconducting Cu/alloy magnets, electronics	Section 232 copper + semis + Section 122	25–65%	HIGH RISK	Cryogenic supply chain from Germany/Japan
X-Ray / Angio Equipment	Steel frames, X-ray tubes, detector arrays	Section 232 steel/semis + Section 122	25–65%	HIGH RISK	China-sourced electrical components carry additional Section 301
Molecular Imaging (PET/SPECT)	Electronics, detectors, pharmaceuticals (tracers)	Section 232 semis + pharma 100% (tracers)	25–115%	HIGH RISK	PET tracers may qualify as pharmaceutical — verify HTS class
Ultrasound Systems	Transducer elements, electronics, cables	Section 232 semis + Section 122	25–40%	WATCH	Lower metal content; primary exposure is semiconductor components
Diagnostics / IVD Reagents	Chemical reagents, APIs, plastics, consumables	Pharma S.232 investigation; Section 122	0–100%	WATCH	Section 122 exemptions may apply; pharma tariff risk remains if classified as drug product
Varian Linac / RT Systems	Electronics, mechanical, steel	Section 232 steel/semis + Section 122	25–65%	WATCH	Significant U.S. domestic manufacturing reduces import exposure
Service Parts / Spare Parts	Varies widely by system	Section 232 applicable by part type + Section 122	10–65%	WATCH	Each HTS code must be mapped individually; broker review required
PPE / Consumables	Gloves, gowns, masks — primarily China-sourced	Section 301 (China) + Section 122	10–80%	HIGH RISK	In scope of Medical Devices Section 232 investigation (PPE included)
Raw Materials (Steel, Al, Cu)	Commodity inputs	Section 232	50%	ACTIVE	No country exemptions remain for steel/aluminum (except UK 25%)

SHS Impact Sources

Country Explorer

Select a country to see currently levied U.S. tariffs (high confidence), contested/conditional programs, country-specific reciprocal rate status, and known countermeasures against U.S. goods.

Country

Canada

Country Summary

U.S. Measures For Selected Country

Rows marked Active are currently levied under available official texts. Rows marked Contested/Conditional depend on post-ruling enforcement actions or future determinations.

Measure	Commodity / Product Scope	Tariff / Treatment	Status	Effective

Countermeasures Against U.S. Goods

Jurisdiction	Known Countermeasure	Product Scope	Status	Effective / Horizon

Country Evidence Links

Commodity Matrix

Commodity-level map of U.S. measures that matter most for sourcing, landed cost, and contract clauses. This table is prefiltered to trade instruments with explicit Federal Register/White House publication records.

Commodity Group	Current U.S. Tariff Condition	Coverage Notes	Status	Primary Sources

Timeline (Key Events)

Chronology includes issuance and major modifications through March 2026. Dates are shown as absolute dates to prevent interpretation drift.

Live Feeds (Official Sources)

Automated intelligence pull from Federal Register API, CBP CSMS, and official retaliation/public-policy feeds. Use this view for daily signal checks and escalation triggers.

Federal Register (Tariff-Relevant)

Date	Type	Document	Query Hit

CBP CSMS (Operations)

Date	Message

Retaliation / Countermeasure Watch

Jurisdiction	Date	Headline	Feed

Coverage in this build: EU Commission, UK DBT, PRC MOFCOM (English), Canada Finance.

Feed Health

Waiting for data load.

HTS Landed-Cost Calculator

Estimator for procurement triage. It combines MFN, Section 232/301, and optional contested IEEPA layers with a configurable non-stacking simplification.

Scenario Inputs

Origin Country

Commodity Program

HTS Code (Optional)

Quantity (Optional)

Customs Value USD

Freight + Insurance USD

MFN Rate %

Section 301 Rate % (if applicable)

Include IEEPA layers (struck down Feb 20 — for historical/refund analysis only) Apply non-stacking simplification (use highest special-duty bucket) Shipment qualifies under USMCA rules of origin Goods are Canada/Mexico energy or potash bucket Goods are in Brazil-targeted Annex product list Include Section 122 global surcharge (10%, effective Feb 24 2026 for covered non-exempt goods) Goods are exempt from Section 122 (pharma, certain ag, critical minerals, some electronics)

Estimated Output

Component	Nominal Rate	Applied Rate	Duty Amount	Note

Assumptions: this estimator is for planning only, not customs entry filing. Use broker/legal review for HTS line-level application, exclusions, AD/CVD, and liquidation risk.

Sourcebook (Reputable / Primary Sources)

Only official government/legal sources are used here for core tariff status. Each source below is directly linked.

Gaps And Next Updates Required

To become a true one-stop Bloomberg-style desk for global procurement, the platform still needs these data integrations and controls.